A phase 1, randomized, double-blind, parallel, pharmacokinetic study of subcutaneous and intramuscular lanreotide in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 30 Sep 2016
At a glance
- Drugs Lanreotide (Primary) ; Lanreotide (Primary)
- Indications Acromegaly
- Focus Pharmacokinetics
- 30 Sep 2016 According to an Ipsen Biopharmaceuticals media release, data from this study were presented at the annual symposium of the North American Neuroendocrine Tumor Society (NANETS).
- 27 Jul 2015 New trial record
- 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.